18-Methoxycoronaridine

18-Methoxycoronaridine
	File:18-methoxycoronaridine2.png
Gene therapy
Clinical data
Physiological data
Legal status
Pharmacokinetic data
Identifiers
	IUPAC name (-)-18-methoxycoronaridine;
CAS Number	266686-77-5;
Chemical and physical data
Formula	C22H28N2O3
Molar mass	368.50 g/mol

Overview

(-)-18-Methoxycoronaridine (18-MC) is a derivative of ibogaine invented in 1996 by the research team around the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont. In animal studies it has proved to be effective at reducing self-administration of morphine, cocaine, methamphetamine and nicotine.^[1] 18MC is a selective α₃β₄ nicotinic antagonist and, opposed to ibogaine, has no affinity at the α₄β₂ subtype nor at NMDA-channels nor at the serotonin transporter.^[2] There is no publication that would indicate that it had ever been tested in humans.

↑ S.D. Glick (1996). "18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats". Brain Res. 719 (1–2): 29–35. PMID 8782860. line feed character in |title= at position 61 (help)
↑ I.M. Maisonneuve (2003). "Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment". Pharmacol. Biochem. Behav. 75 (3): 607–18. PMID 12895678.